Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma (including pseudoexfoliation or pigment dispersion glaucoma) or ocular hypertension.~* Currently on treatment with Travoprost 0.004%/Timolol 0.5% prescribed as approved in the country, on morning or evening dosing for at least 28 days prior to screening, and in the opinion of the Investigator may benefit from further IOP lowering.~* Mean IOP measurements at both the Eligibility 1 and Eligibility 2 visits, in at least 1 eye (the same eye(s) ≥ 19 and ≤ 28 mmHg at 09:00 while on a Travoprost 0.004%/ Timolol 0.5% solution.~* Able to understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee.~* Willing and able to attend all study visits.~Exclusion Criteria:~* Women of childbearing potential: not postmenopausal for at least 1 year or less than 6 weeks since sterilization, currently pregnant; have a positive result on the urine pregnancy test at Screening; intend to become pregnant during the study period; breast-feeding; or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.~* Mean IOP \> 28 mmHg at any time point in either eye during the Screening/Eligibility Phase.~* Any form of glaucoma other than open-angle glaucoma or ocular hypertension.~* Severe central visual field loss in either eye.~* Chronic, recurrent or severe inflammatory eye disease in either eye.~* Ocular trauma in either eye within the past 6 months prior to the Screening visit.~* Ocular infection or ocular inflammation in either eye within the past 3 months prior to the Screening visit.~* Retinal degeneration, diabetic retinopathy, or retinal detachment in either eye.~* Best-corrected visual acuity score worse than 55 ETDRS letters (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal) in either eye.~* Other ocular pathology (including severe dry eye) in either eye that may, in the opinion of the Investigator, preclude the safe administration of any study medication.~* Intraocular surgery in either eye within the past 6 months prior to the Screening visit.~* Ocular laser surgery in either eye within the past 3 months prior to the Screening visit.~* Any other condition including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study.~* Asthma, history of asthma, or severe chronic obstructive pulmonary disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simbrinza + Duotrav (Type: EXPERIMENTAL): Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
- Vehicle + Duotrav (Type: PLACEBO_COMPARATOR): Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues